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Abstract
Background: Reduced nocturnal fall (non-dipping) of blood pressure (BP) is a predictor of cardiovascular target
organ damage. No genome-wide association studies (GWAS) on BP dipping have been previously reported.
Methods: To study genetic variation affecting BP dipping, we conducted a GWAS in Genetics of Drug Responsiveness
in Essential Hypertension (GENRES) cohort (n = 204) using the mean night-to-day BP ratio from up to four ambulatory
BP recordings conducted on placebo. Associations with P < 1 × 10− 5 were further tested in two independent cohorts:
Haemodynamics in Primary and Secondary Hypertension (DYNAMIC) (n = 183) and Dietary, Lifestyle and Genetic
determinants of Obesity and Metabolic Syndrome (DILGOM) (n = 180). We also tested the genome-wide significant
single nucleotide polymorphism (SNP) for association with left ventricular hypertrophy in GENRES.
Results: In GENRES GWAS, rs4905794 near BCL11B achieved genome-wide significance (β = − 4.8%, P = 9.6 × 10− 9 for
systolic and β = − 4.3%, P = 2.2 × 10− 6 for diastolic night-to-day BP ratio). Seven additional SNPs in five loci had P values
< 1 × 10− 5. The association of rs4905794 did not significantly replicate, even though in DYNAMIC the effect was in the
same direction (β = − 0.8%, P = 0.4 for systolic and β = − 1.6%, P = 0.13 for diastolic night-to-day BP ratio). In GENRES,
the associations remained significant even during administration of four different antihypertensive drugs. In separate
analysis in GENRES, rs4905794 was associated with echocardiographic left ventricular mass (β = − 7.6 g/m2, P = 0.02).
Conclusions: rs4905794 near BCL11B showed evidence for association with nocturnal BP dipping. It also associated
with left ventricular mass in GENRES. Combined with earlier data, our results provide support to the idea that BCL11B
could play a role in cardiovascular pathophysiology.
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Background
Blood pressure (BP) follows a diurnal pattern and is gen-
erally lower at night than during the day, defined as BP
dipping [1]. Attenuated nocturnal BP dipping has been
associated with cardiovascular target organ damage and
increased risk for cardiovascular events [2, 3]. Recent
meta-analysis, examining the prognostic significance of
nocturnal systolic BP fall in 17,312 hypertensives from
three continents, demonstrated that blunted nighttime
BP dipping in untreated hypertensive subjects predicted
significantly a variety of cardiovascular end points, in-
cluding coronary events, strokes, cardiovascular deaths
and total deaths [4]. This risk increase was found to be
independent of ambulatory 24-h BP levels [4]. In fact,
international guidelines for hypertension recommend
routine use of 24-h ambulatory BP measurement
(ABPM) to assess the nighttime BP and BP dipping [5].
However, the cause of variation in BP dipping is not well
established. Better understanding of the phenomenon
could help identifying those with increased risk for car-
diovascular morbidity and mortality.
Large scale genome-wide association studies (GWAS)
have identified several susceptibility loci for elevated BP,
which together explain only a few percent of the trait
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variance suggesting that many causal loci remain un-
identified (for review, see [6]). It is thought that improv-
ing accuracy of BP measurements as well as introducing
new phenotypic parameters that better correlate to car-
diovascular risk could lead to discovery of new genetic
loci [6]. Like BP levels, the BP dipping status may be
partly inherited; Wang et al. [7] reported that 59% of the
heritability in systolic BP (SBP) dipping and 81% of the
heritability in diastolic BP (DBP) dipping were due to
genetic influence, arousing interest to find the genes that
affect BP dipping.
In animal studies, mutation or deletion of core circa-
dian genes operating the internal clock resulted in dis-
ruption of the circadian variation of BP [8, 9]. This
hypothesis was tested in two candidate gene studies on
Taiwanese [10] and Chinese [11] populations that re-
ported suggestive associations between certain circadian
gene polymorphisms and BP dipping encouraging fur-
ther research for their role. A different approach was
taken by Wirtwein et al., who recently found that five
risk loci for coronary artery disease (CAD), derived from
GWASs, were also associated with non-dipping status in
patients with CAD [12]. However, no GWASs on BP
dipping have been before reported.
We have previously conducted a GWAS on antihyper-
tensive drug responsiveness in the Genetics of Drug Re-
sponsiveness in Essential Hypertension (GENRES) study
[13], with replication of the data in Finnish participants
of the Losartan Intervention for Endpoint Reduction in
Hypertension (LIFE) study [14]. A special feature of the
GENRES study was the inclusion of four 4-week
drug-free placebo periods in its design [15], generating a
most useful opportunity to obtain repeated ABPMs and
nocturnal BP dipping measurements for every partici-
pant. Here we report our GWAS study on BP dipping,
mostly based on the GENRES study, but also containing
replication data from Finnish patients of two other stud-
ies: Haemodynamics in Primary and Secondary Hyper-
tension (DYNAMIC) [16, 17] and Dietary, Lifestyle and
Genetic determinants of Obesity and Metabolic Syn-
drome (DILGOM) [18].
Methods
Discovery cohort – The GENRES platform
Rationale and results of the GENRES study (clinicaltrials.gov
NCT03276598, registered retrospectively) have been
previously published elsewhere [13–15]. In brief,
GENRES is a double-blind, randomized, placebo-
controlled cross-over study that was designed to search
for genetic variation predicting response to four classes
of antihypertensive drugs, conducted at Helsinki Uni-
versity Hospital between years 1999 and 2004 (Add-
itional file 1: Figure S1). Initially, a total of 313 Finnish
men (aged 35 to 60 years) with moderate hypertension
(DBP ≥ 95 mmHg or previous use of antihypertensive
medication) were screened for the study. Secondary
hypertension, drug-treated diabetes mellitus, congestive
heart failure and CAD were among the exclusion cri-
teria. The study participants underwent 4 different
one-month single-drug treatment periods (losartan
50 mg, amlodipine 5 mg, hydrochlorothiazide 25 mg,
and bisoprolol 5 mg daily) separated by one-month pla-
cebo periods. Twenty-four-hour ABPM was carried out
at the end of each drug and placebo period using a de-
vice equipped with a position sensor (Diasys Integra;
Novacor, Rueil-Malmaison, France). Each subject gave
written informed consent and the study was approved
by the Ethics Committee of Helsinki University Central
Hospital and National Agency of Medicines of Finland.
For the discovery GWAS, we used the ABPMs re-
corded at the end of each placebo period. BP readings
were taken every 15 min when standing and every
30 min when supine. Intense physical activity was not
permitted. Daytime was defined as hours between 7 am
and 10 pm. Single observations were excluded from
the analysis due to low pulse pressure (< 15 mmHg if
SBP < 120 mmHg and < 20 mmHg if SBP > 120 mmHg),
high heart rates (≥ 110 bpm), lying down during daytime,
standing up or being awake at nighttime or high physical
activity. For a recording to be accepted, > 15 daytime
and > 7 nighttime measurements were required. The mean
SBP and DBP dipping of all placebo periods were used as
the study variables. A total of 235 unrelated subjects were
successfully genotyped and had ABPM data from at least
one placebo period. To reduce the effect of day-to-day
variation in the dipping phenotype, only the 204 subjects
that had ≥3 accepted placebo ABPMs available (173 sub-
jects with four and 31 subjects with three ABPMs) were
included in the discovery GWAS.
Replication cohorts
DYNAMIC (clinicaltrials.gov NCT01742702) is an
on-going study to investigate hemodynamic changes in
primary and secondary hypertension with non-invasive
hemodynamic measurement [16, 17]. A total 188 subjects
with ABPM dipping available were genotyped. One
subject was excluded due to low success rates of genotyp-
ing, one subject was excluded due to morbid obesity (body
mass index (BMI) > 40) and 3 subjects were excluded due
to first degree relativeness; ultimately, 183 subjects were
included in this replication cohort. BP was measured with
Microlife WatchBP O3 monitor (Microlife AG, Widnau,
Switzerland) every 20 min during the day (7 am to 10 pm)
and every 30 min during the night (10 pm to 7 am). Single
observations were excluded using the same criteria as de-
scribed for GENRES. Each subject gave written informed
consent and the study was approved by the Ethics
Committee of Tampere University Hospital.
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DILGOM was a population survey conducted in 2007
to assess the effects of environment and genetics on obes-
ity and metabolic syndrome. Four hundred and
ninety-four subjects of DILGOM participated in a cardio-
vascular substudy. In 2014, 290 still living participants of
the cardiovascular substudy underwent re-examination in-
cluding a 24-h ABPM to compare novel and traditional
BP measurement methods [18]. Both BP dipping and gen-
etic data were available for 207 unrelated subjects. Four
subjects that were morbidly obese (BMI > 40) and 23 sub-
jects that were over the age of 75 were excluded, resulting
in 180 subjects to be included in the replication cohort.
BP was measured with a Microlife WatchBP O3 monitor
(Microlife AG, Widnau, Switzerland) every 20 min during
the day (7 am to 10 pm) and every 30 min during the
night (10 pm to 7 am). Night-time BP was defined as the
mean of all BP values of the actual sleeping period and
daytime BP as the mean of all other BP values. Each sub-
ject gave written informed consent and the study was ap-
proved by the Ethics Committee of the Hospital District
of Southwest Finland.
Genotyping methods
The genotyping methods and quality control
steps (including exclusions for identity-by-state
clustering, gender check, Hardy-Weinberg equi-
librium P value < 1 × 10− 5 and minor allele frequency < 0.01)
for GENRES have been described in detail before [13].
The DNA samples of the GENRES study subjects were
genotyped at the Institute for Molecular Medicine
Finland (Helsinki, Finland) using the Illumina
HumanOmniExpress BeadChip (Illumina, San Diego,
CA, USA). After quality control steps a total of 631,844
autosomal SNPs were available for the analysis. Subse-
quent imputation was performed using IMPUTE2 [19]
and the Hapmap2 CEU release 22 reference panel after
pre-phasing with ShapeITv2. However, only the geno-
typed SNPs were used for the GWAS analysis.
The DNA samples of the DYNAMIC study subjects
were genotyped at the Institute for Molecular Medicine
Finland (Helsinki, Finland) using the Illumina HumanOm-
niExpress BeadChip (Illumina, San Diego, CA, USA). One
subject was excluded due to low success rate (< 95%). The
six SNPs used for replication passed the same quality con-
trol steps as described for GENRES above.
The genotype data of the DILGOM study subjects was
derived from previously conducted GWASs. The DILGOM
DNA samples were genotyped with Illumina
Cardio-MetaboChip and Illumina 610 K arrays (Illumina,
San Diego, CA, USA) at the Wellcome Trust Sanger
Institute (Cambridge, UK) and the Institute for Molecular
Medicine Finland (Helsinki, Finland). Unobserved SNPs
were imputed using 1000 Genomes haplotypes Phase I in-
tegrated variant set release (ShapeITv2) in NCBI build 37
version June 2014. If the selected SNP was not genotyped,
then the imputed value was used. Info scores for the im-
puted SNPs used were 0.989 for rs16984571 and 0.998 for
rs1230361.
Left ventricular hypertrophy in GENRES
Left ventricular hypertrophy (LVH) was assessed in
GENRES from the transthoracic echocardiograms re-
corded during the first placebo period and from electro-
cardiograms (ECGs) recorded at the end of each placebo
period [20]. Echocardiographically determined left
ventricular mass (LVM, in grams) was calculated as
0.8 × [1.04 × ((interventricular septal thickness + left ven-
tricular end-diastolic diameter + posterior wall thick-
ness)3 – left ventricular end diastolic diameter3)] + 0.6
and left ventricle mass index (LVMI) by dividing LVM
by body surface area (square meters). LVMI was avail-
able for 227 GENRES subjects that were successfully ge-
notyped for rs4905794. The standard resting 12-lead
ECG was recorded with Marquette MAC 5000 electro-
cardiograph (GE Marquette Medical Systems,
Milwaukee, Wisconsin, USA) at the end of each placebo
period and all measurements were performed blinded to
all other data. Sokolow-Lyon voltage (SV1 + RV5 or SV1
+ RV6, whichever was greater) and Cornell voltage-
duration product [(SV3 + RaVL) × QRS duration] were
used as markers of LVH. The indices were calculated
from digital ECGs from automatically made ECG mea-
surements with a visual confirmation for all subjects
who had completed the whole study. Mean values of all
placebo periods were used. A total of 185 subjects, that
were successfully genotyped for rs4905794, had these
ECG measurements available.
Statistical analysis
Baseline demographics and BP dipping data of all study
subjects were analyzed using IBM SPSS Statistics 22.0
(IBM Corp., Armonk, NY, USA). SBP and DBP dipping
were analyzed separately as continuous variables, and
were calculated as night-to-day BP ratio [3] and
expressed as percentage [(mean nighttime BP / mean
daytime BP) × 100]. Both variables were adjusted for cor-
responding daytime BP using linear regression. Lifestyle
factors (age, BMI, waist-hip ratio, antihypertensive use
before entry to the study, duration of hypertension,
smoking, serum creatinine level and daily urinary excre-
tion of sodium after the first placebo period were tested
for association with stepwise linear regression and in-
cluded as covariates if P value for association was < 0.10
for either systolic or diastolic night-to-day BP ratio. The
final regression models are presented in Additional file 2:
Table S1. These regression variables were approximately
normally distributed. The effect of population stratifica-
tion on night-to-day BP ratio was tested with principal
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components (PCs) generated with program Smartpca
from Eigensoft package [21]. A reduced dataset of 114,487
SNPs with r2 < 0.5 and the long-range linkage disequilib-
rium (LD) regions excluded [22] was used. Three signifi-
cant PCs for population stratification with P values < 0.10
were identified with program Twstats from Eigensoft
package, but they were not associated with either
systolic or diastolic night-to-day BP ratio residuals (all
P values > 0.30) and were thus not included in GWAS
analysis. The discovery GWAS was done using
covariate-adjusted night-to-day BP ratio residuals and
linear regression under additive genetic model in
PLINK v1.07 [23]. P values < 5 × 10− 8 were considered
as genome-wide-level significant, while P values < 1 × 10− 5
were considered as suggestively significant.
The statistically most significant SNPs from each locus
with P value < 1 × 10− 5 were selected for replication in
two independent Finnish cohorts. For the replication co-
horts similar statistical approach was used. Bonferroni
corrected P value < 0.004 was regarded as a successful
replication [0.05 / (2 studies × 6 SNPs)], considering that
systolic and diastolic dipping are highly correlated.
P value < 0.05 with the same direction of effect was
considered as suggestive replication. We also conducted
meta-analyses of the top BP dipping (night-to-day BP ra-
tio) SNPs in all available studies using inverse-variance
model with fixed effects in METAL [24]. We defined sig-
nificant results as P values < 5 × 10− 8. P values < 1 × 10− 5
were considered to represent a suggestive association.
In addition, we tested association of the genome-wide-
significant SNP (rs4905794) with LVMI, Sokolow-Lyon
voltage and Cornell voltage-duration product measured
in GENRES subjects to further explore the nature of the
SNP in relation to target organ damage. We tested for
significant covariates and adjusted LVMI with age
(standardized β = 3.3, P = 0.007) and Sokolow-Lyon volt-
age with BMI (standardized β = − 0.6, P = 0.0003) using
stepwise linear regression (other covariates tested were
smoking, waist-hip ratio and previous use of antihyper-
tensive medication). BP levels were not included as co-
variates (although highly significant) as we presumed the
effect of the genotypes to be principally mediated
through BP levels. No covariates were significant for
Cornell voltage-duration product.
A SNP set-based approach was used to test for associ-
ation of circadian genes with BP dipping (night-to-day BP
ratio). The 24 genes listed in the circadian rhythm path-
way in KEGG (Kyoto Encyclopedia of Genes and
Genomes) PATHWAY database [25, 26] were selected for
testing. All successfully genotyped SNPs located inside the
transcript boundaries of each circadian gene were in-
cluded. Transcript boundaries of the circadian genes were
derived from Ensembl Genome Browser (release 87, in
NCBI37/hg19) [27, 28]. The set-based tests were
conducted in PLINK v1.07 [23]. Using the SBP and DBP
dipping (night-to-day BP ratio) residuals calculated as de-
scribed above, a mean statistic was calculated for each
gene based on the single-SNP association results under a
linear model. Single SNPs were included in the set if asso-
ciation P value was < 0.05 and r2 was < 0.5 with other
SNPs selected with maximum of five SNPs included for
each gene. The dataset was then permuted 10,000 times
calculating empirical P value for each gene describing the
number of times the permuted set-statistic exceeded the
original one for the gene. Bonferroni corrected P value of
0.002 (0.05/24) was used to correct for multiple testing
(24 genes).
Finally, we sought to replicate the previously published
genetic associations, based on candidate gene studies,
with BP dipping. This included five SNPs from Leu et al.
[10], two SNPs from Sheng et al. [11] (one of which is
shared with Leu et al.) and five SNPs from Wirtwein
et al. [12]. Two of these SNPs were not genotyped in
GENRES and thus imputed values were used. We con-
sidered Bonferroni corrected P value < 0.0045 (0.05/11
SNPs tested) and the same direction of effect as success-
ful replication and P value < 0.05 and the same direction
of effect as suggestive replication.
Functional analysis for top associations
We assessed the consequence of the leading SNPs of the
loci that achieved P value < 1 × 10− 5, using VEP (variant
effect predictor) database [29, 30]. To look for putative
functional consequences, we annotated each SNP to the
closest gene using Ensembl database (release 87) [27, 28]
and conducted an expression quantitative trait locus
(eQTL) analysis in publicly available Genotype Tissue
Expression (GTEx) database [31, 32]. We then used Phe-
noScanner [33, 34] to find if any of the SNPs had previ-
ously reported cardiovascular trait associations at a
nominal significance of P < 0.05.
The Neale lab has made available basic GWAS results
for over 2000 phenotypes from the UK Biobank data of
~ 337,000 unrelated individuals of British ancestry [35].
We looked up our leading SNPs for BP dipping through
MR-Base PheWAS database [36] to see if they were as-
sociated with SBP or DBP, or with seven sleep traits
(sleep duration, getting up in morning, chronotype, nap
during day, sleeplessness, snoring, daytime dozing) in
the Neale lab data, at a nominal significance of P < 0.05.
Results
Genome-wide association study in GENRES
The baseline characteristics of GENRES subjects (the
discovery sample) are described in Table 1. Ambulatory
BP data used for calculation of the mean BP dipping
during placebo administration was derived from four
(n = 173) or three (n = 31) recordings. The Manhattan
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plots of the GWAS results for BP dipping from the dis-
covery cohort are shown in Fig. 1 and the
quantile-quantile plots are depicted in Additional file 3:
Figure S2. As detailed in Table 2, one locus (rs4905794 at
chromosome 14q32.2 near BCL11B) reached genome-
wide significance threshold for SBP dipping (systolic
night-to-day BP ratio β = − 4.8%, P = 9.6 × 10− 9). The asso-
ciation of rs4905794 was very similar for DBP dipping
(diastolic night-to-day BP ratio β = − 4.3%, P = 2.2 × 10− 6).
Further five potential loci were identified with suggestive
significance (P < 1 × 10− 5) (Table 2). Local Manhattan
plots of the best loci are presented in Additional file 4:
Figure S3A-F. A total of 99 SNPs in 62 loci had P values
< 1 × 10− 4 for either SBP or DBP dipping.
The GENRES subjects received four different antihyper-
tensive monotherapies in a rotational fashion separated by
one-month placebo periods (Additional file 1: Figure S1).
We also tested if the associations of the statistically most
significant SNPs from the six loci with P < 1 × 10− 5 de-
rived from the placebo periods were similar when dipping
data during drug administration was analyzed. The results
are shown in Additional file 5: Figure S4A-F. The effects
of the SNPs were consistently in the same direction as
during placebo periods and the associations remained sta-
tistically significant.
Replication analysis in DYNAMIC and DILGOM
In the replication step, the lead SNPs (most significantly
associated SNP) from the genome-wide significant locus
and the five loci with P values < 1 × 10− 5 were followed
up in two independent Finnish cohorts, DYNAMIC and
DILGOM (Table 1). The majority of the DYNAMIC
subjects had elevated blood pressure while DILGOM
comprised mostly of normotensive individuals (Table 1).
The results of the replication analysis are summarized in
Table 2. In DYNAMIC, rs4905794 showing genome-
wide significance in GENRES had an effect in the same
direction, but the association was not statistically signifi-
cant (β = − 0.8%, P = 0.4 for systolic night-to-day BP ratio
and β = − 1.6%, P = 0.13 for diastolic night-to-day BP ra-
tio). The association did not, however, replicate in the
population-based DILGOM cohort. Nocturnal BP dip-
ping (night-to-day BP ratio) values according to
rs4905794 genotypes in the three study samples are il-
lustrated in Fig. 2. Another SNP, rs16984571 located in
KCNS3 intron, showed effect in the same direction as in
GENRES in both replication cohorts, but the associa-
tions did not reach statistical significance. In a
meta-analysis of all three studies (combined n = 567)
employing inverse-variance model with fixed effects no
SNP showed genome-wide significant P values
(Additional file 2: Table S2).
Association of rs4905794 with markers of left ventricular
hypertrophy in GENRES
To explore the possible association of the genome-wide-
significant SNP (rs4905794) with markers of cardiovascular
target organ damage, we tested for the association of this
SNP with indices of LVH in GENRES. Using all GENRES
subjects with LVMI and rs4905794 genotype data available
(n = 227, mean LVMI 98.1 ± 18.5 g/m2), rs4905794 was
found to significantly associate with LVMI, with the allele
associated with larger dipping also associating with smaller
left ventricular mass (G allele β = − 7.6 g/m2, P = 0.02)
(Fig. 3a). In the 185 GENRES subjects with ECG recordings
and rs4905794 genotype available, the mean Sokolow-Lyon
voltage was 25.6 ± 6.7 mm and mean Cornell voltage-
duration product was 1444 ± 528 mm×ms. The rs4905794
genotype was associated with Sokolow-Lyon voltage (G al-
lele β = − 2.8 mm, P = 0.03) (Fig. 3b). For Cornell
voltage-duration product this association had a tendency to
the same direction (G allele β = − 112 mm×ms, P = 0.3)
(Fig. 3c). If BP dipping was included as a covariate in
Table 1 Clinical characteristics of the discovery cohort (GENRES)
and replication cohorts (DYNAMIC and DILGOM)
Variables GENRES DYNAMIC DILGOM
n 204 183 180
Age (years) 50.7 ± 6.3 47.5 ± 11.7 56.3 ± 11.4
Men (%) 100 60 47
Body Mass Index (kg/m2) 26.4 ± 2.7 27.1 ± 4.2 26.6 ± 4.4
Waist-hip ratio 0.99 ± 0.05 0.91 ± 0.08 0.91 ± 0.09
Current smokers (%) 15.7 15.3 7.8
Blood pressure levels (mmHg)
Office measurements
SBP 152 ± 13 145 ± 18 129 ± 18
DBP 100 ± 7 92 ± 12 79 ± 10
Ambulatory recordings
Daytime
SBP 144 ± 10 140 ± 13 128 ± 12
DBP 99 ± 6 88 ± 8 78 ± 8
Nighttime
SBP 118 ± 11 118 ± 13 112 ± 12
DBP 81 ± 6 71 ± 9 65 ± 8
Nocturnal dipping
Night-to-day BP ratio (%)
SBP 81.9 ± 5.3 84.2 ± 5.7 87.8 ± 6.2
DBP 81.9 ± 4.8 80.4 ± 6.4 83.7 ± 8.1
Percentage of non-dippers (%)
7 16 32
Non-dipper is defined as night-to-day BP ratio > 90% for either systolic or diastolic
blood pressure dipping. Values are presented as mean mean ± standard deviation.
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure,
BP blood pressure
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the analyses, the P values for the associations
remained the same.
Association of BP dipping with circadian gene polymorphisms
In GENRES GWAS, no SNPs mapping within the
transcript boundaries of the selected circadian genes had
P values < 1 × 10− 4 (Additional file 2: Table S3). Using
set-based tests to evaluate the combined effect of inde-
pendent SNPs in each gene, the retinoic acid-related or-
phan receptor genes (RORA, RORB, RORC) had the
smallest P values (Additional file 2: Table S4). RORB had
a suggestively significant P value 0.03 for association
with SBP dipping, but this association did not survive
multiple testing. Replication analysis for circadian gene
SNPs from two earlier candidate gene studies is summa-
rized in Additional file 2: Table S5. These SNPs did not
significantly replicate in our study.
Replication of previously reported associations of CAD
SNPs and BP dipping
In our study, rs9818870 was associated with both systolic
and diastolic night-to-day BP ratio (β = 1.4%, P = 0.03 and
β = 2.3%, P = 0.002, respectively) in consistent direction
(Additional file 2: Table S5), thus further supporting the
association of this SNP with BP dipping. The associations
of the other four CAD SNPs found by Wirtwein et al. [12]
did not significantly replicate in our study.
Discussion
We report here the first GWAS on nocturnal BP dipping.
When using a sample of hypertensive patients subjected
to repeated (mostly four times) 24-h ABPMs on placebo, a
specific SNP (rs4905794) reached genome-wide signifi-
cance for association with this phenotype, and five add-
itional loci showed P values < 1 × 10− 5. It is noteworthy
that the associations of all six SNPs remained very
Fig. 1 Manhattan plots of the association P values from the discovery GWAS in GENRES. (a) SBP dipping (b) DBP dipping. The y-axis shows the -log10(P values)
of each genotyped SNP and the x-axis shows their chromosomal position. The horizontal lines correspond to genome-wide (5 × 10−8) and
suggestive (1 × 10− 5) P value thresholds. SNPs above the suggestive threshold are annotated. Abbreviations: GWAS; genome-wide association
study; SBP, systolic blood pressure; DBP, diastolic blood pressure; SNP; single nucleotide polymorphism
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consistent even when the analyses were conducted during
administration of four different antihypertensive drug
monotherapies. We sought to replicate the findings in two
independent Finnish populations. Compared to GENRES,
rs4905794 showed similar, although not statistically sig-
nificant, association with BP dipping in DYNAMIC,
comprising both hyper- and normotensive individuals, but
did not replicate in DILGOM, consisting of a
population-based sample of individuals. rs4905794 was
also associated with LVMI and Sokolow-Lyon voltage in
GENRES.
rs4905794 maps to intergenic region on chromosome
14 that is thought to harbor various regulatory features
that affect expression of the nearby BCL11B gene [37].
In eQTL analysis using publicly available gene expres-
sion data sets, rs4905794 was associated with BCL11B
expression in hippocampus (n = 111, P = 0.001 in GTEx
database [31, 32], Additional file 2: Table S6) and in pu-
tamen (n = 133, P = 0.0001 in Braineac database [38, 39])
with the same direction of effect. rs4905794 has
previously been associated with blood lipoprotein(a)
level (P = 7.6 × 10− 5 in NHLBI Family Heart Study [40]
data published in database of genotypes and phenotypes
(dbGaP) [41, 42]), a well-defined cardiovascular risk fac-
tor [43], that has been shown to closely correlate with
nighttime BP level and nocturnal BP dipping [44].
BCL11B codes for a zinc-finger type transcription fac-
tor that has an established role in development and
maintenance of central nervous system and regulation of
T-cell development (for review, see ref. [45]). However,
the role of BCL11B in regulation BP is not known. A
recent GWAS on carotid-femoral pulse-wave velocity,
the standard measurement of aortic stiffness, identified
SNPs mapping to the same potential 3′ enhancer region
near BCL11B at genome-wide significance and the top
SNP (rs1381289) was also associated with increased risk
for CAD events and heart failure [46]. Interestingly,
Cherrier et al. have shown that BCL11B has a protective
role in cardiomyocytes by repressing P-TEFb-mediated
intercellular signaling that otherwise results in hyper-
trophic cardiomyopathy in mice [47]. In addition, experi-
mental data supports a role for BCL11B in the direct
regulation of circadian rhythm. BCL11B was shown to
interact with histone deacetylase 1 (HDAC1) [48], and
the nucleosome remodeling and histone deacetylase
(NuRD) complex [49]. Both HDAC1, as a complex with
SIN3 [50], and the NuRD complex [51] are in turn in-
volved in the regulation of rhythmic expression of mam-
malian circadian clock PER genes in vitro. In summary,
BCL11B could affect BP regulation and target organ
damage through various mechanisms including the regu-
lation of circadian rhythm, supporting the findings from
our GWAS.
Available expression and phenotype databases seem to
provide support for the role of some of the lead SNPs
reported in the present study (Additional file 2: Tables
S6 and S7). Three specific SNPs turned out to be eQTLs
for nearby genes. Firstly, there was a strong correlation
between intergenic SNP rs1230361 genotype and endo-
plasmic reticulum aminopeptidase 2 (ERAP2) expression
in all available GTEx datasets (meta-analysis P value
1.0 × 10− 200) [31, 32]. In a previous candidate gene study
Table 2 Top SNPs associated with blood pressure dipping (night-to-day blood pressure ratio) in GENRES and replication in DYNAMIC
and DILGOM
Discovery GWAS in GENRES Replication in DYNAMIC Replication in DILGOM
SNP Chr Gene EA/ OA SBP/
DBP
EAF n β (%) P EAF n β
(%)
P Direction EAF n β
(%)
P Direction
rs4905794 14 BCL11B G/A SBP 0.08 204 −4.8 9.6 × 10−9 0.10 183 −0.8 0.4 same 0.11 180 0.9 0.3 opposite
eQTL DBP −4.3 2.2 × 10−6 −1.6 0.13 same 1.0 0.4 opposite
rs2119704 14 GPR65 A/C SBP 0.07 204 −2.9 1.7 × 10−3 0.06 183 1.4 0.2 opposite 0.06 180 0.9 0.5 opposite
eQTL DBP −4.6 3.4 × 10−6 1.1 0.4 opposite −0.4 0.8 same
rs10817396 9 SNX30 G/A SBP 0.17 204 1.9 2.4 × 10−3 0.18 183 0.3 0.7 same 0.20 180 0.3 0.7 same
intron DBP 3.1 5.5 × 10−6 −0.1 0.9 opposite 0.6 0.6 same
rs16984571 2 KCNS3 G/A SBP 0.15 201 −2.7 5.6 × 10−6 0.14 183 −0.8 0.3 same 0.13 180 −1.2 0.2 same
intron DBP −2.5 1.1 × 10−4 −0.7 0.4 same −1.0 0.4 same
rs12509878 4 lncRNA C/A SBP 0.34 203 −1.5 9.8 × 10−4 0.37 183 1.3 0.03 opposite 0.37 180 −1.4 0.03 same
intron DBP −2.2 5.8 × 10−6 1.1 0.11 opposite −1.6 0.05 same
rs1230361 5 ERAP2 A/C SBP 0.47 204 1.4 1.1 × 10−3 0.49 183 0.5 0.4 same 0.45 180 −0.6 0.3 opposite
intron/eQTL DBP 2.1 9.3 × 10−6 0.1 0.9 same −0.7 0.3 opposite
SNPs with P < 1 × 10−5 for SBP or DBP dipping (covariate-adjusted systolic or diastolic night-to-day BP ratio using additive genetic model) in the discovery GWAS
(GENRES) are shown in order of significance. Explanation for selection of related candidate gene is shown under gene name. Abbreviations: GWAS genome-wide
association study, SNP single nucleotide polymorphism, Chr chromosome, EA effect allele, OA other allele, SBP systolic blood pressure, DBP diastolic blood pressure,
EAF effect allele frequency, eQTL expression quantitative trait locus
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rs2549782 (r2 = 0.40, D’ = 0.69 with rs1230361 in GEN-
RES) was shown to be associated with pre-eclampsia
[52]. Also, in UK Biobank GWAS data [35, 36],
rs1230361 was nominally associated with DBP (P = 0.002)
supporting the role of this SNP in blood pressure regula-
tion, and with two out of seven available sleep traits
(getting up in morning, chronotype). Secondly,
rs2119704 was an eQTL for GPR65 expression (meta-a-
nalysis P value 2.2 × 10− 10), and rs10817396 for SNX30
expression (meta-analysis P value 4.1 × 10− 7) in
selected tissues from the GTEx database [31, 32].
rs10817396 was also associated with both SBP
(P = 0.03) and DBP (P = 0.01) and two out of seven
available sleep traits (chronotype, sleeplessness) in UK
Biobank GWAS data [35, 36]. It is also noteworthy,
that intronic rs16984571 (KCNS3), which had an ef-
fect in consistent direction in both replication co-
horts, also associated with chronotype in UK Biobank
GWAS data. KCNS3 codes for a subunit (Kv9.3) of
voltage-gated K+ channel that regulates the contrac-
tion of arterial smooth muscle [53].
Circadian clock genes have been shown to regulate BP
in animal studies [8, 9]. In our GWAS of BP dipping,
there were no SNPs showing P values < 1 × 10− 4 and
mapping to circadian genes, and in set-based tests no
gene showed enrichment of small P values. We could
not replicate the positive associations of circadian gene
polymorphisms with BP dipping reported by Leu et al.
[10] and Sheng et al. [11]. However, the carriers of A al-
lele of rs3816358 of BMAL1 that associated with
non-dipping in both Taiwanese (OR = 1.50, P = 0.03) [9]
and Chinese (β = 3.25%, P = 0.04) [10] subjects had
reduced SBP (β= 0.8%, P= 0.2) and DBP (β= 1.0%, P= 0.18)
dipping in GENRES. We attempted to replicate the
findings of Wirtwein et al. [12] on five CAD risk loci
derived from large GWAS studies that were associated
with non-dipping status and found that the A allele of
rs9818870 in MRAS was significantly associated with
Fig. 2 Mean nocturnal blood pressure dipping according to rs4905794 genotypes in the three study samples. (a) SBP dipping (systolic night-to-day
blood pressure ratio) (b) DBP dipping (diastolic night-to-day blood pressure ratio). Error bars indicate standard error of means. Abbreviations: SBP,
systolic blood pressure; DBP, diastolic blood pressure
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reduced SBP and DBP dipping in our hypertensive pa-
tients with no evidence of CAD.
The present study has several important limitations.
The limited sample size of the discovery cohort
(GENRES) and the relatively small sizes of the available
replication cohorts constitute an obvious issue. Second,
while GENRES and one of the replication samples
(DYNAMIC) were dominated by hypertensive individ-
uals, the other (DILGOM) was derived from a popula-
tion survey. This may have caused a selection bias in
GENRES. In addition the definition of awake and sleep
period was different in DILGOM compared to GENRES
and DYNAMIC. Together, these two issues may have
caused smaller effect sizes of the test variable (nocturnal
BP dipping), resulting in possible false negative findings
in DILGOM. Third, both men and women were in-
cluded in DYNAMIC and DILGOM, while GENRES
consisted of men only. On the other hand, the main
strength of our study is the use of repeated (mostly four
times) ABPMs during placebo in GENRES. We also be-
lieve that acquisition of parallel data under the four dif-
ferent drug monotherapies in GENRES strongly support
our data. Even though the results should be interpret
with caution due to the small sample size, they encour-
age further studies using novel well-defined phenotypes
to find new genetic associations in human hypertension.
Conclusions
To our knowledge, our study is the first GWAS con-
ducted on BP dipping in human hypertension. Using a
carefully controlled pharmacogenetic study platform, we
found a genome-wide significant association between BP
dipping and rs4905794 near BCL11B gene, with similar
tendency in another hypertensive patient cohort; how-
ever it was not replicated in a population based sample.
rs4905794 was also associated with markers of LVH. In
addition, we found some support for the association be-
tween BP dipping and rs9818870, previously suggested
to associate with nondipping pattern in patients with
CAD. In contrast, we did not find evidence that poly-
morphisms of circadian clock genes would play a
marked role in determining BP dipping. Together with
previous evidence, our results encourage further re-
search into the role of BCL11B in pathophysiology of
human hypertension.
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